{
  "id": 11176382,
  "title": "Kallyope rebrands after Novo obesity deal, gets $94M for Phase 3 migraine drug",
  "url": "https://urgent.news/2026/10/01/kallyope-rebrands-after-novo-obesity-deal-gets-94m-for-phase-3",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T11:00:48.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/kallyope-rebrands-after-novo-obesity-deal-gets-94m-for-phase-3-migraine-drug/"
  },
  "original_language": "en",
  "account": null,
  "summary": "New York City drug developer Kallyope is rebranding as TriGemX Bio as it focuses solely on treating migraine. To support the restructured company and its Phase 3 trials of a former Tanabe Pharma drug, TriGemX ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 6,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal",
        "url": "https://urgent.news/2026/09/29/hengrui-pharma-shares-rise-as-novo-nordisk-signs-2-6-billion-drug-deal",
        "published": "2026-09-29T05:16:50.000Z"
      },
      {
        "outlet": "Seeking Alpha News",
        "title": "Novo Nordisk strikes $2.6B obesity drug deal with China's Hengrui",
        "url": "https://urgent.news/2026/09/29/novo-nordisk-strikes-2-6b-obesity-drug-deal-with-chinas-hengrui",
        "published": "2026-09-29T05:56:34.000Z"
      },
      {
        "outlet": "Endpoints News",
        "title": "Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug",
        "url": "https://urgent.news/2026/09/29/novo-to-spend-300m-upfront-to-license-hengruis-weekly-oral-weight",
        "published": "2026-09-29T11:04:17.000Z"
      },
      {
        "outlet": "BioPharma Dive",
        "title": "Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill",
        "url": "https://urgent.news/2026/09/29/novo-to-pay-hengrui-up-to-2-6b-for-a-once-weekly-obesity-pill",
        "published": "2026-09-29T15:52:00.000Z"
      },
      {
        "outlet": "Semafor",
        "title": "Pharma giant Novo licenses Chinese weight-loss drug",
        "url": "https://urgent.news/2026/09/30/pharma-giant-novo-licenses-chinese-weight-loss-drug",
        "published": "2026-09-30T10:58:39.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}